MAN 4720 Nov. 15‚ 2011 Merck‚ the FDA‚ and the Vioxx Recall In 1999 the Food and Drug Administration (FDA) had approved Vioxx‚ what would become Merck’s “blockbuster” drug. Although the FDA had approved the drug there was uncertainty of the safety of drug. Vioxx was approved to treat a variety of conditions‚ such as osteoarthritis and acute pain‚ but there was also a chance that it would increase cardiovascular problems. What I found most interesting about this case was the changes in how drugs
Premium Pharmacology Advertising Clinical trial
CASE 5.1: MERCK ACQUISITION OF MEDCO Abstract Corporate mergers and acquisitions (M&A) have become popular across the globe during the last two decades due to globalization‚ liberalization‚ technological developments‚ and competitive business environment (Fisher & Siburg‚ 2009). The synergistic gains from M&A may result from efficient management‚ economies of scale‚ profitable use of assets‚ exploitation of market power‚ and the use of complementary resources (Mitchell
Premium Pharmacology Pharmaceutical industry Pharmacy
Merck‚ the FDA‚ and the VIOXX Recall MBA 520 Ethics and Leadership in a Global Environment 11.15.2009 MBA 520 15 November 2009 Merck‚ the FDA‚ and the VIOXX Recall In 1999‚ Merck started a clinical trial called VIGOR‚ checking the effectiveness of VIOXX in patients with gastrointestinal problems‚ and in this trial they noted for the first time that patients taking VIOXX suffered roughly twice as many heart attacks and strokes as those taking the control‚ Naproxen.
Premium Social responsibility Clinical trial Corporate social responsibility
Effects of Leadership in the Management Strategies of Merck and Company‚ Inc. Rana Satnani MGT-330 Management: Theory‚ Practice‚ and Application. July 2‚ 2010 Carolyn Harrison There lies a division in the business world between managers who “do things right” and leaders who “do the right things” (Bennis‚ 2007‚ p. 13). The primary difference between good managers and fantastic leaders is the ability to take risks and make independent decisions. Ethical leadership is more important today than
Premium Leadership Management Business ethics
Merck‚ the FDA‚ and the Vioxx Recall 1. Do you believe that Merck acted in a socially responsible and ethical manner with regard to Vioxx? Why or Why not? In your answer‚ please address the company’s drug development and testing‚ marketing and advertising‚ relationships with government regulators and policymakers‚ and handling of the recall. I do not believe that Merck made a socially responsible decision when Vioxx was introduced into the pharmaceutical market. Scientists that were involved
Premium Pharmacology
License – Case Study Acknowledgement Kanchan Sharma * Introduction * Case study – Ist compulsory license issued by India * Terms under which Compulsory License is Issued * Conclusion * References INTRODUCTION Compulsory licensing is when a government allows someone else to produce the patented product without the consent of the patent owner. The patent owner still enjoys the rights over patent .He is paid by the Licensee some amount as a royalty for his patent. The TRIPS
Premium Patent Royalties Patent law
Merck and river blindness are a good example for Utilitarianism theory because the results brought happiness for both the company and the people. Utilitarianism is an ethical framework that focuses on the outcomes or results of actions. In fact‚ its name comes from the Greek word Telos‚ which means “end.” The two most influential developers of the utilitarian viewpoint were Englishmen Jeremy Bentham (1748–1832) and John Stuart Mill (1806–1873). Under this framework‚ acting ethically means making
Premium John Stuart Mill Ethics Jeremy Bentham
Acquisition between Merck and Schering-Plough Introduction On March 9‚ 2009‚ Merck & Co.‚ Inc. and Schering-Plough Corporation announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine‚ under the name Merck in a stock and cash transaction. As the two companies’ combined 2008 revenues were $47 billion. The deal officially closed on November 3‚ 2009. Background of the two parties Merck & Co. (NYSE: MRK)
Premium
Software Licensing and Pricing Software is a mature industry with considerable cost pressures. It costs an incredible amount of money to develop‚ deliver‚ market‚ sell and support a software product. Software vendors are struggling with dwindling margins‚ increased competition‚ and bad economy that keep pushing them to sell at lower prices. For many‚ the only way to overcome that is to make big shifts in licensing and pricing schemes. Traditionally‚ most software vendors use a perpetual
Premium Software industry Software development Software as a service
10/6/2014 Case 3: Merck and River Blindness 1. Why was Merck hesitant about developing a human version of Ivermectin? Merck considered this opportunity as a high risk investment. The cost of developing the drug was estimated at $100 million. Even if it was successful to cure river blindness the victims were too poor to afford the drug. There was no way to distribute it in these rural areas were the victims were located. In addition‚ there was a possibility that people would misuse the drugs‚ which
Premium Onchocerciasis Human